查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1890971

按适应症、剂量、给药途径、分销管道、年龄层、最终用户和地区分類的磺达肝癸钠市场

Fondaparinux Market, By Indication, By Dosage Strength, By Route of Administration, By Distribution Channel, By Age Group, By End User, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3个工作天内

价格
简介目录

据估计，2025 年磺达肝癸钠市值为 7.355 亿美元，预计到 2032 年将达到 11.354 亿美元，2025 年至 2032 年的复合年增长率为 6.4%。

报告内容 报告详情
基准年： 2024 2025年市场规模： 7.355亿美元
历史数据时期： 2020-2024 预测期： 2025-2032
预测期间（2025-2032年）： 6.40% 2032 年的预测值： 11.354亿美元

全球磺达肝癸钠市场在抗凝血剂产业中占据重要地位，它主要是一种合成五糖药物，用于预防和治疗血栓性栓塞症。

磺达肝癸钠（主要以Arixtra等商品名销售）是一种选择性Xa因子抑制剂，与传统的肝素抗凝血剂相比，其药理特性更优。这种合成化合物具有极佳的生物利用度、可预测的药物动力学，且肝素诱导的血小板减少性疾病减少症风险较低，因此日益成为全球医疗保健机构的首选治疗方案。

该市场涵盖了多种临床应用领域，例如预防深层静脉栓塞症、治疗肺动脉栓塞以及外科手术（尤其是整形外科手术）的手术全期手术期抗凝血管理。

心血管疾病盛行率上升、全球人口老化、外科手术数量增加以及人们对血栓性栓塞症併发症的认识不断提高，正在推动市场显着扩张。世界各地的医疗系统都认识到磺达肝癸钠的临床优势，例如每日一次给药的便利性、药物相互作用少以及安全性高，这些优势促使其在医院和门诊环境中得到广泛应用，从而为市场的持续增长奠定了基础。

市场动态

由于多种有利因素，全球磺达肝癸钠市场正经历强劲成长。主要驱动因素是全球心血管疾病和血栓栓塞性疾病负担日益加重，导致不同患者族群对有效抗凝血治疗的需求不断增长。全球人口老化也是市场成长的重要因素，因为老年患者发生静脉血栓栓塞症的风险较高，因此需要预防和治疗性介入。磺达肝癸钠凭藉其卓越的疗效和安全性，满足了这项需求。

外科手术量不断增加，尤其是包括髋关节和膝关节关节重建术在内的整形外科手术，对可靠的抗凝血通讯协定产生了巨大的需求，而磺达肝癸钠因其可预测的药物动力学和较低的监测要求而成为首选药物。

然而，该药物的市场成长受到诸多限制，主要原因是其高成本高于传统抗凝血剂（如未分级肝素） ，这使得价格敏感的医疗市场难以负担，也限制了其在资源匮乏地区的应用。此外，儘管其发生严重出血併发症的风险低于传统抗凝血剂，但出血风险仍然是一个临床问题，影响药物的配发模式，并需要严格的患者筛选和监测通讯协定。

透过在癌症相关血栓症管理和门诊抗凝血治疗等新兴治疗领域拓展适应症，市场蕴藏着巨大的机会。磺达肝癸钠凭藉着便利性和安全性优势，展现出强大的竞争优势。非专利药进入各个区域市场，为提高药物可近性和市场渗透率创造了机会，尤其是在开发中国家，成本因素对治疗决策有显着影响。同时，正在进行的探索新适应症和联合治疗的临床研究有望开发新的收入来源，并扩大目标患者群体。

本次调查的主要特点

  • 本报告对全球磺达肝癸钠市场进行了详细分析，以 2024 年为基准年，给出了预测期（2025-2032 年）的市场规模和復合年增长率（%）。
  • 它还指出了每个细分市场的潜在商机，并说明了该市场具有吸引力的投资提案矩阵。
  • 该研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或核准、市场趋势、区域展望以及主要企业。
  • 该研究根据以下参数对全球磺达肝癸钠市场的主要企业进行了分析：公司概况、产品系列、主要亮点、财务表现和策略。
  • 本报告的研究结果将帮助负责人和经营团队就即将推出的产品、类型升级、市场扩张和行销策略做出明智的决策。
  • 这份全球磺达肝癸钠市场报告面向该行业的各种相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
  • 相关人员可以透过全球磺达肝癸钠市场分析中使用的各种策略矩阵轻鬆做出决策。

目录

第一章 研究目标与前提条件

  • 调查目的
  • 先决条件
  • 简称

第二章 市场范围

  • 报告概述
    • 市场定义和范围
  • 执行摘要

第三章：市场动态、监理及趋势分析

  • 市场动态
  • 司机
  • 抑制因素
  • 机会
  • 影响分析
  • 法规环境
  • 产品上市及核准
  • PEST分析
  • 波特分析
  • 併购趋势
  • 产业趋势

4. 2020-2032年全球磺达肝癸钠市场依适应症划分

  • 静脉血栓栓塞症(VTE) 预防
  • 深层静脉栓塞症（DVT）治疗
  • 肺动脉栓塞（PE）治疗
  • 急性冠状动脉症候群（ACS）

5. 2020-2032年全球磺达肝癸钠市场（依剂量划分）

  • 2.5mg
  • 5mg
  • 7.5mg
  • 10mg

6. 2020-2032年全球磺达肝癸钠市场依给药途径划分

  • 预填充式注射器
  • 管瓶

7. 2020-2032年全球磺达肝癸钠市场依通路划分

  • 医院药房
  • 零售药房
  • 网路药房

8. 2020-2032年全球磺达肝癸钠市场依年龄层划分

  • 成人
  • 老年人
  • 儿童

9. 2020-2032年全球磺达肝癸钠市场（依最终用户划分）

  • 医院
  • 专科诊所
  • 门诊手术中心
  • 专业心臟中心
  • 诊断中心
  • 居家医疗机构

10. 2020-2032年全球磺达肝癸钠市场（依地区划分）

  • 北美洲
    • 美国
    • 加拿大
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 其他拉丁美洲国家
  • 欧洲
    • 德国
    • 英国
    • 西班牙
    • 法国
    • 义大利
    • 俄罗斯
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳洲
    • 韩国
    • ASEAN
    • 亚太其他地区
  • 中东
    • GCC
    • 以色列
    • 其他中东国家
  • 非洲
    • 南非
    • 北非
    • 中非

第十一章 竞争格局

  • Sanofi
  • Viatris
  • Dr Reddy's Laboratories Ltd
  • Aurobindo Pharma Ltd
  • GlaxoSmithKline plc
  • Jiangsu Hengrui Medicine Co Ltd
  • Aspen API
  • BrightGene Bio-Medical Technology Co Ltd
  • Formosa Laboratories Inc
  • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
  • ScinoPharm Taiwan Ltd
  • Pfizer Inc
  • Eugia Pharma Specialities Ltd
  • Fresenius Kabi
  • Hikma Pharmaceuticals plc

第十二章 分析师建议

  • 机会
  • 一致的机会地图

第十三章 参考文献与调查方法

  • 参考
  • 调查方法
  • 关于出版商
简介目录
Product Code: CMI8953

Fondaparinux Market is estimated to be valued at USD 735.5 Mn in 2025 and is expected to reach USD 1,135.4 Mn by 2032, growing at a compound annual growth rate (CAGR) of 6.4% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 735.5 Mn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 6.40% 2032 Value Projection: USD 1,135.4 Mn

The global fondaparinux market represents a critical segment within the anticoagulant pharmaceutical industry, focusing on synthetic pentasaccharide medications designed to prevent and treat thromboembolic disorders.

Fondaparinux, marketed primarily under brand names such as Arixtra, functions as a selective Factor Xa inhibitor, offering superior pharmacological properties compared to traditional heparin-based anticoagulants. This synthetic compound demonstrates exceptional bioavailability, predictable pharmacokinetics, and reduced risk of heparin-induced thrombocytopenia, making it an increasingly preferred therapeutic option for healthcare providers worldwide.

The market encompasses various clinical applications including deep vein thrombosis prevention, pulmonary embolism treatment, and perioperative anticoagulation management across surgical procedures, particularly orthopedic interventions.

Growing prevalence of cardiovascular diseases, aging global population demographics, increasing surgical procedures, and rising awareness regarding thromboembolic complications are driving substantial market expansion. Healthcare systems worldwide are recognizing fondaparinux's clinical advantages, including once-daily dosing convenience, minimal drug interactions, and enhanced safety profiles, contributing to its growing adoption in both hospital and outpatient settings, positioning this market for sustained growth trajectory.

Market Dynamics

The global fondaparinux market experiences robust growth driven by multiple compelling factors, with the primary driver being the escalating global burden of cardiovascular diseases and thromboembolic disorders, necessitating effective anticoagulation therapies across diverse patient populations. The aging demographic worldwide significantly contributes to market expansion, as elderly patients face heightened risks of venous thromboembolism, requiring prophylactic and therapeutic interventions where fondaparinux demonstrates superior efficacy and safety profiles.

Increasing surgical procedures, particularly orthopedic surgeries including hip and knee replacements, create substantial demand for reliable anticoagulation protocols, with fondaparinux emerging as the preferred choice due to its predictable pharmacokinetics and reduced monitoring requirements.

However, market growth faces significant restraints, primarily centered around the medication's high cost compared to traditional anticoagulants like unfractionated heparin, creating affordability challenges in price-sensitive healthcare markets and limiting adoption in resource-constrained settings. Additionally, the risk of major bleeding complications, though lower than conventional anticoagulants, remains a clinical concern that influences prescribing patterns and requires careful patient selection and monitoring protocols.

The market presents substantial opportunities through expanding applications in emerging therapeutic areas, including cancer-associated thrombosis management and outpatient anticoagulation programs, where fondaparinux's convenience and safety advantages offer competitive positioning. Generic formulations entering various regional markets create opportunities for increased accessibility and market penetration, particularly in developing economies where cost considerations significantly influence treatment decisions, while ongoing clinical research exploring novel indications and combination therapies promises to unlock additional revenue streams and expand the addressable patient population.

Key Features of the Study

  • This report provides in-depth analysis of the global fondaparinux market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global fondaparinux market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Sanofi, Viatris, Dr Reddy's Laboratories Ltd, Aurobindo Pharma Ltd, GlaxoSmithKline plc, Jiangsu Hengrui Medicine Co Ltd, Aspen API, BrightGene Bio-Medical Technology Co Ltd, Formosa Laboratories Inc, Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd, ScinoPharm Taiwan Ltd, Pfizer Inc, Eugia Pharma Specialities Ltd, Fresenius Kabi, and Hikma Pharmaceuticals plc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global fondaparinux market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fondaparinux market

Market Segmentation

  • Indication Insights (Revenue, USD Mn, 2020 - 2032)
    • Venous Thromboembolism (VTE) Prophylaxis
    • Deep Vein Thrombosis (DVT) Treatment
    • Pulmonary Embolism (PE) Treatment
    • Acute Coronary Syndrome (ACS)
  • Dosage Strength Insights (Revenue, USD Mn, 2020 - 2032)
    • 2.5 mg
    • 5 mg
    • 7.5 mg
    • 10 mg
  • Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
    • Pre-filled Syringes
    • Vials
  • Distribution Channel Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Age Group Insights (Revenue, USD Mn, 2020 - 2032)
    • Adult
    • Geriatric
    • Pediatric
  • End User Insights (Revenue, USD Mn, 2020 - 2032)
    • Hospitals
    • Specialty Clinics
    • Ambulatory Surgical Centers
    • Specialty Cardiac Centers
    • Diagnostic Centers
    • Homecare Settings
  • Regional Insights (Revenue, USD Mn, 2020 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Sanofi
    • Viatris
    • Dr Reddy's Laboratories Ltd
    • Aurobindo Pharma Ltd
    • GlaxoSmithKline plc
    • Jiangsu Hengrui Medicine Co Ltd
    • Aspen API
    • BrightGene Bio-Medical Technology Co Ltd
    • Formosa Laboratories Inc
    • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
    • ScinoPharm Taiwan Ltd
    • Pfizer Inc
    • Eugia Pharma Specialities Ltd
    • Fresenius Kabi
    • Hikma Pharmaceuticals plc

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Fondaparinux Market, By Indication
    • Global Fondaparinux Market, By Dosage Strength
    • Global Fondaparinux Market, By Route of Administration
    • Global Fondaparinux Market, By Distribution Channel
    • Global Fondaparinux Market, By Age Group
    • Global Fondaparinux Market, By End User
    • Global Fondaparinux Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends

4. Global Fondaparinux Market, By Indication, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Venous Thromboembolism (VTE) Prophylaxis
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Deep Vein Thrombosis (DVT) Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Pulmonary Embolism (PE) Treatment
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Acute Coronary Syndrome (ACS)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

5. Global Fondaparinux Market, By Dosage Strength, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • 2.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 7.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

6. Global Fondaparinux Market, By Route of Administration, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pre-filled Syringes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Vials
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

7. Global Fondaparinux Market, By Distribution Channel, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

8. Global Fondaparinux Market, By Age Group, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adult
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Geriatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Pediatric
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

9. Global Fondaparinux Market, By End User, 2020-2032, (USD Mn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospitals
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Specialty Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Ambulatory Surgical Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Specialty Cardiac Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Diagnostic Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)
  • Homecare Settings
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Mn)

10. Global Fondaparinux Market, By Region, 2020 - 2032, Value (USD Mn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Mn)
    • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Mn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Mn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Dosage Strength, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By End User, 2020 - 2032, Value (USD Mn)
    • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Mn)
      • South Africa
      • North Africa
      • Central Africa

11. Competitive Landscape

  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Viatris
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dr Reddy's Laboratories Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aurobindo Pharma Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Jiangsu Hengrui Medicine Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Aspen API
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • BrightGene Bio-Medical Technology Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Formosa Laboratories Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • ScinoPharm Taiwan Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Pfizer Inc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Eugia Pharma Specialities Ltd
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Fresenius Kabi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Hikma Pharmaceuticals plc
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

12. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

13. References and Research Methodology

  • References
  • Research Methodology
  • About us